These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

109 related articles for article (PubMed ID: 37006072)

  • 1. Is FGFR4 Gly388Arg missense variant a suitable prognostic marker in neuroblastoma?
    Katarzyna S
    J Cancer Res Ther; 2023; 19(2):355-358. PubMed ID: 37006072
    [TBL] [Abstract][Full Text] [Related]  

  • 2. FGFR4 Arg388 allele is associated with resistance to adjuvant therapy in primary breast cancer.
    Thussbas C; Nahrig J; Streit S; Bange J; Kriner M; Kates R; Ulm K; Kiechle M; Hoefler H; Ullrich A; Harbeck N
    J Clin Oncol; 2006 Aug; 24(23):3747-55. PubMed ID: 16822847
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The fibroblast growth factor receptor-4 Arg388 allele is associated with gastric cancer progression.
    Ye Y; Shi Y; Zhou Y; Du C; Wang C; Zhan H; Zheng B; Cao X; Sun MH; Fu H
    Ann Surg Oncol; 2010 Dec; 17(12):3354-61. PubMed ID: 20844967
    [TBL] [Abstract][Full Text] [Related]  

  • 4. FGFR4 Gly388Arg Polymorphism Affects the Progression of Gastric Cancer by Activating STAT3 Pathway to Induce Epithelial to Mesenchymal Transition.
    Ye Y; Li J; Jiang D; Li J; Xiao C; Li Y; Han C; Zhao C
    Cancer Res Treat; 2020 Oct; 52(4):1162-1177. PubMed ID: 32599983
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A Polymorphism in the FGFR4 Gene Is Associated With Risk of Neuroblastoma and Altered Receptor Degradation.
    Whittle SB; Reyes S; Du M; Gireud M; Zhang L; Woodfield SE; Ittmann M; Scheurer ME; Bean AJ; Zage PE
    J Pediatr Hematol Oncol; 2016 Mar; 38(2):131-8. PubMed ID: 26840079
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Fibroblast growth factor receptor 4 Gly388Arg polymorphism in Chinese gastric cancer patients.
    Shen YY; Lu YC; Shen DP; Liu YJ; Su XY; Zhu GS; Yin XL; Ni XZ
    World J Gastroenterol; 2013 Jul; 19(28):4568-75. PubMed ID: 23901234
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Meta and pooled analyses of FGFR4 Gly388Arg polymorphism as a cancer prognostic factor.
    Frullanti E; Berking C; Harbeck N; Jézéquel P; Haugen A; Mawrin C; Parise O; Sasaki H; Tsuchiya N; Dragani TA
    Eur J Cancer Prev; 2011 Jul; 20(4):340-7. PubMed ID: 21412156
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Gender-Specific Association Between FGFR4 Gly388Arg Gene Variants and Hypertension.
    Al-Daghri NM; Mohammed AK; Al-Attas OS; Draz HM; Alokail MS
    Genet Test Mol Biomarkers; 2017 Jul; 21(7):422-427. PubMed ID: 28650667
    [TBL] [Abstract][Full Text] [Related]  

  • 9. FGFR4 profile as a prognostic marker in squamous cell carcinoma of the mouth and oropharynx.
    Dutra RL; de Carvalho MB; Dos Santos M; Mercante AM; Gazito D; de Cicco R; Group G; Tajara EH; Louro ID; da Silva AM
    PLoS One; 2012; 7(11):e50747. PubMed ID: 23226373
    [TBL] [Abstract][Full Text] [Related]  

  • 10. FGFR4 polymorphism, TP53 mutation, and their combinations are prognostic factors for oral squamous cell carcinoma.
    Tanuma J; Izumo T; Hirano M; Oyazato Y; Hori F; Umemura E; Shisa H; Hiai H; Kitano M
    Oncol Rep; 2010 Mar; 23(3):739-44. PubMed ID: 20127014
    [TBL] [Abstract][Full Text] [Related]  

  • 11.
    Cho SH; Hong CS; Kim HN; Shin MH; Kim KR; Shim HJ; Hwang JE; Bae WK; Chung IJ
    Cancer Res Treat; 2017 Jul; 49(3):766-777. PubMed ID: 27857023
    [TBL] [Abstract][Full Text] [Related]  

  • 12. FGFR4 Gly388Arg polymorphism may affect the clinical stage of patients with lung cancer by modulating the transcriptional profile of normal lung.
    Falvella FS; Frullanti E; Galvan A; Spinola M; Noci S; De Cecco L; Nosotti M; Santambrogio L; Incarbone M; Alloisio M; Calabrò E; Pastorino U; Skaug V; Haugen A; Taioli E; Dragani TA
    Int J Cancer; 2009 Jun; 124(12):2880-5. PubMed ID: 19296538
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Fibroblast growth factor receptor 4 single nucleotide polymorphism Gly388Arg in head and neck carcinomas.
    Wimmer E; Ihrler S; Gires O; Streit S; Issing W; Bergmann C
    World J Clin Oncol; 2019 Mar; 10(3):136-148. PubMed ID: 30949443
    [TBL] [Abstract][Full Text] [Related]  

  • 14. FGFR4 Arg388 allele correlates with tumour thickness and FGFR4 protein expression with survival of melanoma patients.
    Streit S; Mestel DS; Schmidt M; Ullrich A; Berking C
    Br J Cancer; 2006 Jun; 94(12):1879-86. PubMed ID: 16721364
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Fibroblast growth factor receptor 4 mutation and polymorphism in Japanese lung cancer.
    Sasaki H; Okuda K; Kawano O; Yukiue H; Yano M; Fujii Y
    Oncol Rep; 2008 Nov; 20(5):1125-30. PubMed ID: 18949411
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The Prognostic Significance of FGFR4 Gly388 Polymorphism in Esophageal Squamous Cell Carcinoma after Concurrent Chemoradiotherapy.
    Shim HJ; Shin MH; Kim HN; Kim JH; Hwang JE; Bae WK; Chung IJ; Cho SH
    Cancer Res Treat; 2016 Jan; 48(1):71-9. PubMed ID: 25989802
    [TBL] [Abstract][Full Text] [Related]  

  • 17. FGFR4 Is a Potential Predictive Biomarker in Oral and Oropharyngeal Squamous Cell Carcinoma.
    Koole K; van Kempen PM; van Bockel LW; Smets T; van der Klooster Z; Dutman AC; Peeters T; Koole R; van Diest P; van Es RJ; Willems SM
    Pathobiology; 2015; 82(6):280-9. PubMed ID: 26551585
    [TBL] [Abstract][Full Text] [Related]  

  • 18. FGFR4 Gly388Arg polymorphism contributes to prostate cancer development and progression: a meta-analysis of 2618 cases and 2305 controls.
    Xu B; Tong N; Chen SQ; Hua LX; Wang ZJ; Zhang ZD; Chen M
    BMC Cancer; 2011 Feb; 11():84. PubMed ID: 21349172
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Involvement of the FGFR4 Arg388 allele in head and neck squamous cell carcinoma.
    Streit S; Bange J; Fichtner A; Ihrler S; Issing W; Ullrich A
    Int J Cancer; 2004 Aug; 111(2):213-7. PubMed ID: 15197773
    [TBL] [Abstract][Full Text] [Related]  

  • 20. FGFR4 Arg388 genotype is associated with pathological complete response to neoadjuvant chemotherapy for primary breast cancer.
    Marmé F; Werft W; Benner A; Burwinkel B; Sinn P; Sohn C; Lichter P; Hahn M; Schneeweiss A
    Ann Oncol; 2010 Aug; 21(8):1636-1642. PubMed ID: 20147743
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.